27/04/2026
Most cardiac risks develop silently.
By the time a patient walks into a clinic with symptoms, the underlying risk has often been present for years; undetected, unaddressed.
At the OPD level, a doctor typically has access to blood pressure readings, visible symptoms and family history.
What is often missing is the most important piece of information: the patientโs genetic cardiac risk profile.
SmartCardio changes that.
It is a genetic test designed to help doctors make more informed treatment decisions, right from the very first visit.
By analysing key genes that influence how the body responds to cardiac medication, SmartCardio enables doctors to select the right drug, at the right dose, for the right patient before treatment even begins.
Here is a simple example.
A patient visits the OPD after a heart stent procedure.
The doctor plans to prescribe Clopidogrel. Without genetic testing, there is no way to know if the patient can properly activate the drug.
With SmartCardio, a poor metaboliser is identified early, an alternative is prescribed and the risk of clot formation is avoided.
That is the practical value of precision diagnostics at the OPD level.
